PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34314849-10	2021	RA treatment in a dose-dependent manner prevented the overproduction of tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), and IL-6 in both the HIP and PFC.	rosmarinic acid	0-2	tumor necrosis factor	Rattus norvegicus	72-99	
34314849-10	2021	RA treatment in a dose-dependent manner prevented the overproduction of tumor necrosis factor-alpha (TNF-alpha), interleukin 1 beta (IL-1beta), and IL-6 in both the HIP and PFC.	rosmarinic acid	0-2	tumor necrosis factor	Rattus norvegicus	101-110	
25735949-3	2015	Oral administration of RA (100 mg/kg b.w) significantly (p < 0.05) increased the insulin sensitivity index (ISI0,120), while the levels of blood glucose, HbA1c, advanced glycation end products (AGE), TNF-alpha, IL-1beta, IL 6, NO, p-JNK, P38 MAPK and NF-kappaB were significantly reduced, with a concomitant elevation in the plasma insulin levels in diabetic rats.	rosmarinic acid	23-25	tumor necrosis factor	Rattus norvegicus	203-212	
35455434-3	2022	Our findings showed that low-dose RA (10-25 muM) did not influence the cell viability and morphology of A7r5 cells and significantly inhibited LPS-induced mRNA expression of the pro-inflammatory mediators TNFalpha, IL-8, and inducible NO synthase (iNOS).	rosmarinic acid	34-36	tumor necrosis factor	Rattus norvegicus	205-213	
35455434-4	2022	Consistently, RA reduced the production of TNFalpha, IL-8, and NO by A7r5 cells with exposure to LPS.	rosmarinic acid	14-16	tumor necrosis factor	Rattus norvegicus	43-51	
28675794-10	2018	Furthermore, RA ameliorated the increased liver mass, serum levels of ALT, AST, LDH, TNF-alpha, and IL-6 in ethanol group.	rosmarinic acid	13-15	tumor necrosis factor	Rattus norvegicus	85-94	
26429925-8	2016	Plasma TNF-alpha level was found to be decreased in the RA-treated rats.	rosmarinic acid	56-58	tumor necrosis factor	Rattus norvegicus	7-16	
26364660-5	2015	Pretreatment with RA significantly ameliorated pancreas histopathological changes, decreased amylase and lipase activities in serum, lowered myeloperoxidase activity in the pancreas, reduced systematic and pancreatic interleukin-1 beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) levels, and inhibited NF-kappaB translocation in pancreas.	rosmarinic acid	18-20	tumor necrosis factor	Rattus norvegicus	258-285	
26364660-5	2015	Pretreatment with RA significantly ameliorated pancreas histopathological changes, decreased amylase and lipase activities in serum, lowered myeloperoxidase activity in the pancreas, reduced systematic and pancreatic interleukin-1 beta (IL-1beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) levels, and inhibited NF-kappaB translocation in pancreas.	rosmarinic acid	18-20	tumor necrosis factor	Rattus norvegicus	287-296	
25210763-14	2015	In addition, RA supplementation reduces the expressions of tumor necrosis factor-alpha, interlukin-6, and cyclooxygenase-2, and modulates the expression of p65.	rosmarinic acid	13-15	tumor necrosis factor	Rattus norvegicus	59-86